GlassScriptPhysician profile
Monica Passi
NPI 1568859031
$5,745.35
in general payments reported to CMS, 2019-2025
25 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,155 · 2023: $1,039 · 2024: $853 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $2,027.55 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Boston Scientific Corporation | $1,018.43 | 2022-2024 | Exalt Model D, X-Tack Endoscopic Helix Tacking System |
| Abbvie INC. | $763.96 | 2022-2025 | |
| Pfizer INC. | $316.51 | 2022-2025 | |
| Celgene Corporation | $261.19 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.63 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $224.83 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $218.40 | 2022-2024 | Stelara, Remicade, Simponi |
| Madrigal Pharmaceuticals | $97.03 | 2025 | Rezdiffra |
| Ardelyx, INC. | $80.77 | 2022-2023 | Ibsrela |
| Gilead Sciences, INC. | $66.34 | 2023-2024 | |
| Medtronic, INC. | $52.10 | 2025 | Pillcam |
| Genzyme Corporation | $44.83 | 2023-2025 | |
| Amgen INC. | $42.47 | 2022-2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $42.32 | 2023 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $39.62 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $36.06 | 2022 | |
| Phathom Pharmaceuticals, INC. | $32.38 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $31.96 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $26.58 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $22.15 | 2023 | |
| Ferring Pharmaceuticals INC. | $19.73 | 2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $18.16 | 2024 | Givlaari |
| Capsovision, INC. | $15.04 | 2024 | Capsocam Plus |
| Evoke Pharma, INC. | $14.31 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Passi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.